The marker combinations are unlimited and, depending on the panel and markers, are able to show activation of markers, such as OX40 in tumor cells (CK + OX40 +) and rare cells, such as cytotoxic T-cells that express immune checkpoints (e.g., CD3, CD8, PD-1, and PD-L1; Figure 5). This evidence concerns the gene CD8A and neoplasm.